ERIS LIFESCIENCES
|
|
| BOM : 540596 NSE : ERIS | |
| LT :
Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
| ST :
Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : None or < 25% |
Aug 30,2024 |
|
Price(EOD): ₹ 1,389.90
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 18,916.54 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ERIS LIFESCIENCES | 9.1% | 22.6% | 64.3% |
| SUN PHARMACEUTICAL INDUSTRIES | 2.7% | 6% | 62.4% |
| CIPLA | 3.9% | 7.3% | 33.9% |
| DR REDDYS LABORATORIES | 1.2% | 4.2% | 20.1% |
| ZYDUS LIFESCIENCES | 1.8% | -9.5% | 80.1% |
| DIVIS LABORATORIES | 3.2% | 3.5% | 37.8% |
FUNDAMENTAL ANALYSIS OF ERIS LIFESCIENCES
[ Q(TTM): Jun2024, Y: Mar2023
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF ERIS LIFESCIENCES
[As on : Aug 30,2024
]
| Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
48.15
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 392.83 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 7.31
P/B Calculated based on Book Value of Rs 2,586.12 Cr
[Latest Year - Mar2024 - Consolidated Results ] 8.36
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 2,262.24 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
109% 25% 15% |
SHARE PRICE MOMENTUM OF ERIS LIFESCIENCES
ERIS LIFESCIENCES vs SENSEX
DEBT OF ERIS LIFESCIENCES
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2023 2022 2021 Avg_3yrs |
0.14 0 0 0.05 |
0.38 0.02 0 0.13 |
|
[Last Annual Data : Mar2023]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF ERIS LIFESCIENCES
| Pledged Promoter Shares |
10.95 % | |
|---|---|---|
| As on : Dec2023 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF ERIS LIFESCIENCES
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
30.64% 68.42% 50.46% 12.29% |
54.24% 47.27% 2.52% -4.52% |
| QtrlyTrend |
6 | |
| Latest Qtr: Jun2024 | ||
| Quarterly Result Analysis → | ||
ERIS LIFESCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE HEALTHCARE | 2.5% | 7.5% | 54.8% |
| S&P BSE 500 | 1.3% | 1.2% | 39.5% |
| S&P BSE ALLCAP | 1.2% | 1.2% | 40.7% |
| S&P BSE 250 SMALLCAP | 1.1% | 1.2% | 53% |
| S&P BSE 400 MIDSMALLCAP | 1.1% | 0.9% | 53.3% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY 500 | 1.4% | 1.3% | 40.2% |
| NIFTY500 MULTICAP 50:25:25 | 1.3% | 1.2% | 44.8% |
| NIFTY MID SMALL400 | 1.2% | 0.9% | 52.9% |
| NIFTY SMALLCAP250 | 0.9% | 1% | 57% |
You may also like the below Video Courses
FAQ about ERIS LIFESCIENCES
Is ERIS LIFESCIENCES good for long term investment?
As on Aug 30,2024, the Fundamentals of ERIS LIFESCIENCES look Strong and hence it may be good for long term investment! See Financial Performance of ERIS LIFESCIENCES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is ERIS LIFESCIENCES UnderValued or OverValued?
As on Aug 30,2024, ERIS LIFESCIENCES is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of ERIS LIFESCIENCES ?
As on Aug 30,2024, the Intrinsic Value of ERIS LIFESCIENCES is Rs. 1,116.07 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 663.50
Fair Value [Median EV / Sales Model] : Rs. 1,116.07
Fair Value [Median Price / Sales Model] : Rs. 1,210.40
Estimated Median Fair Value of ERIS LIFESCIENCES : Rs. 1,116.07
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
